Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Positive Results for Nash’s Crohn’s Lead Compound Study

Stockhouse Editorial December 3, 2018

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease

GlobeNewswire December 3, 2018

Nash Pharmaceuticals 2: Scaling the Patent Cliff

Jeff Nielson November 27, 2018

NASH Pharmaceuticals 1: Fast-Tracking Pharma Success

Jeff Nielson November 20, 2018

Nash Pharma Sees Results for Lead Compound in Kidney Disease

Stockhouse Editorial November 19, 2018

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease

GlobeNewswire November 19, 2018

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease

GlobeNewswire November 13, 2018

Breathtec Provides Update on FAIMS Breathalyzer Development Program

GlobeNewswire November 5, 2018

Nash Pharma Reports Positive Pre-Clinical Results

Stockhouse Editorial November 2, 2018

Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease

GlobeNewswire November 1, 2018

Breathtec Announces Closing of Private Placement

GlobeNewswire October 24, 2018

Breathtec Announces Acquisition of Nash Pharmaceuticals

GlobeNewswire October 22, 2018

Breathtec to Complete Share Consolidation

GlobeNewswire October 16, 2018

Breathtec Announces Signing of Definitive Agreement to Acquire Nash Pharmaceuticals

GlobeNewswire October 9, 2018

Breathtec to Participate in the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15

GlobeNewswire September 14, 2018

Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year

GlobeNewswire September 13, 2018

Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025

PR Newswire August 3, 2018

Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.

GlobeNewswire August 2, 2018

Breathtec Biomedical Announces Appointment of CEO

GlobeNewswire March 1, 2018

Next-Gen Diagnostic Device Moves Closer to Commercialization

Stockhouse Editorial January 26, 2018